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Abstract  
The clinical use of cyclophosphamide and ifosfamide is limited by a resultant bladder toxicity 
which has been attributed to the metabolite acrolein.  Another metabolite chloroacetaldehyde 
(CAA) associated with nephrotoxicity, has not been investigated for toxicity in the bladder and 
this study investigates the effects of acrolein and CAA on human urothelial cells in vitro.  
Human urothelial cells (RT4 and T24) were treated with acrolein or CAA and changes in cell 
viability, reactive oxygen species, caspase-3 activity and release of urothelial mediators ATP, 
acetylcholine, PGE2 were measured.  The protective effects of N-acetyl cysteine (NAC) were 
also assessed. Both metabolites were toxic to human urothelial cells however, CAA 
significantly decreased cell viability at a 10-fold lower concentration (10µM) than acrolein 
(100µM).  This was associated with increased ROS production and caspase-3 activity. NAC 
protected cells from these changes.  In RT4 cells 100µM acrolein caused a significant increase 
in basal and stretch-induced ATP, Ach and PGE2 release. In T24 cells chloroacetaldehyde 
(10µM) increased basal and stimulated ATP and PGE2 levels.  Again, NAC protected against 
changes in urothelial mediator release following acrolein or CAA. This study is the first to 
report that CAA in addition to acrolein contributes to the urotoxicity of cyclophosphamide and 
ifosfamide.  Both metabolites altered urothelial mediator levels which could contribute to the 
sensory and functional bladder changes experienced by patients after treatment with 
cyclophosphamide or ifosfamide.  Alterations in urothelial cell viability and mediator release 
may be causally linked to oxidative stress, with NAC providing protection against these 
changes. 
 
Keywords: Cyclophosphamide, chloroacetaldehyde, acrolein, ifosfamide, urothelium, 
urotoxicity, oxidative stress, N-acetyl cysteine  
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Introduction 
Cyclophosphamide and ifosfamide are common chemotherapeutic and immunosuppressive 
agents extensively used in the treatment of numerous cancers and chronic autoimmune 
disorders (Lawson et al. 2008).   A major limiting factor in the use of cyclophosphamide and 
ifosfamide is their bladder toxicity which can result in life threatening hemorrhagic cystitis 
(Coggins et al. 1960; Korkmaz et al. 2007).  This toxicity limits the dose and frequency of 
administration of these drugs and hence the full efficacy of these drugs and their clinical 
outcomes may not be fully realised.  Even after the adoption of co-administering the water 
soluble anti-oxidant mesna as a uroprotective agent, a high incidence of bladder toxicity is still 
observed with severe hematuria being reported in up to 10% of patients receiving these drugs 
for cancer treatment (Fukuoka et al. 1991).  In addition, patients can experience lasting side 
effects such as pain when urinating, frequency and pelvic pain which affect their ongoing 
quality of life (Fukuoka et al. 1991).  As a result of these common urotoxic effects, 
cyclophosphamide and ifosfamide are also frequently used in experimental models to induce 
cystitis (Aronsson et al. 2012; Deberry et al. 2014; Golubeva et al. 2014).   
 
Ifosfamide is more toxic than cyclophosphamide and its metabolism favours detoxification 
over therapeutic activation requiring a dose double that of cyclophosphamide to produce a 
similar concentration of active drug (Lawson et al. 2008). The metabolite acrolein is produced 
during activation of both cyclophosphamide and ifosfamide and it is almost exclusively blamed 
for the urotoxicity of these drugs.  Acrolein is excreted in the urine and as a result comes into 
direct contact with the urothelium (Al-Rawithi et al. 1998; Brock et al. 1979) which is an 
important regulator of bladder function (Birder and Andersson 2013).  However, another toxic 
metabolite excreted in the urine is chloroacetaldehyde (CAA) which is produced during 
detoxification of both cyclophosphamide and ifosfamide.  CAA has been linked to the neuro-, 
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cardio- and nephro-toxicity of these drugs (Goren et al. 1986; Joqueviel et al. 1997; Sladek 
1988) while its possible contribution to uro-toxicity has been ignored.  Furthermore, these 
metabolites would be present in the urine together and their combined effects are yet to be 
investigated in the bladder.  Very little is known about the actual concentrations of acrolein 
and CAA appearing in the urine of patients treated with cyclophosphamide and ifosfamide.    
One study has reported the peak concentration of acrolein in the urine of 19 patients receiving 
cyclophosphamide or ifosfamide as 100nM (Takamoto et al. 2004).   While CAA 
concentrations up to 35μM have been measured in plasma (Pendyala et al. 2000), the urinary 
concentration has not yet been reported.   
 
It has been suggested that the main mechanism by which acrolein causes bladder damage is 
through the production of reactive oxygen species (ROS) and nitric oxide (NO) (Korkmaz et 
al. 2007),   resulting in lipid peroxidation, protein oxidation and DNA damage, depletion of 
nicotinamide adenine dinucleotide (NAD) and ATP ultimately causing necrotic cell death 
(Korkmaz et al. 2007). Acrolein can also bind to lysine, histidine and cysteine residues of 
proteins and nucleophilic sites in DNA resulting in widespread protein and DNA modification, 
potentially altering cell function (Beauchamp et al. 1985; Kehrer and Biswal 2000; Korkmaz 
et al. 2007).  CAA toxicity has also been suggested to occur by similar mechanisms including 
depletion of cellular reduced glutathione, NAD and ATP, disturbed Ca2+ signalling, and lipid 
peroxidation, potentially leading to cell necrosis and death (Nissim et al. 2006; Schwerdt et al. 
2006; Sood and O'Brien 1993). 
 
Acrolein and CAA are excreted in the urine and therefore come into direct contact with the 
urothelium potentially altering bladder function or compromising the urothelial barrier 
allowing toxins to pass into the bladder wall.  The urothelium functions as a physical barrier 
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between the underlying cells and urine, but also plays important roles in regulating detrusor 
contraction (Hawthorn et al. 2000) and mechanosensation (Birder 2010).  The urothelium 
responds to bladder filling by releasing chemical mediators such as ATP, acetylcholine (ACh), 
prostaglandin E2 (PGE2) and cytokines to communicate with underlying cells such as sensory 
nerves, interstitial cells and smooth muscle (Birder et al. 2010). Disruption of these 
mechanisms are associated with bladder dysfunction such as painful bladder 
syndrome/interstitial cystitis (Kumar et al. 2007) and bladder overactivity (Kumar et al. 2010) 
Therefore, this study aimed to investigate the effect of the cyclophosphamide and ifosfamide 
metabolites, acrolein and CAA, on the viability and function of human urothelial cells in vitro 




RT4 and T24 cells were used in this study as a model of urothelial function.  RT4 cells have 
been used previously as a model of urothelial mediator release (Kang et al. 2013b; Mansfield 
and Hughes 2014). Both cell lines were obtained from the European Collection of Cell Cultures 
(ECACC) and were grown and maintained at 37◦C with 5% CO2 in McCoy’s 5A culture 
medium (Invitrogen, Victoria, Australia) containing L-glutamine, phenol red, 10% fetal bovine 
serum (FBS) and 500 U/mL penicillin-streptomycin (Invitrogen, Victoria, Australia).  Cell 
viability was assessed by trypan blue exclusion. 
 
Following seeding and incubation for 24 hrs, cells were treated with cyclophosphamide (0-
100µM), ifosfamide (0-100µM), acrolein (0-100µM), CAA (0-10µM) or a combination of 
acrolein (100nM) and CAA (10µM) in culture medium for a further 24 hrs. A matched control, 
which received culture medium only, was also examined during each experiment.  To 
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investigate the potential protective effects of N-acetyl cysteine (NAC) cells were treated as 
described above but in the presence of NAC (300µM and 1mM).  Cells were then ready for the 
following investigations.  
 
Resazurin proliferation assay 
Reduction of the redox dye resazurin to resorufin was used to measure the viability of cell 
cultures (Anoopkumar-Dukie et al. 2005).  Cells were seeded at 1.35 x 104 trypan blue-
excluding cells in 200µl of medium in 96-well microtiter plates.  Following drug treatment the 
medium above the cells was removed, wells were washed twice with phosphate buffered saline 
(PBS) and 200µl of fresh medium containing 44µM resazurin was added to each well.  After 
optimum incubation (2 hr or 1 hr for RT4 and T24 cell lines respectively), reduction of 
resazurin to resorufin was determined by fluorescence (excitation 530nM; emission 590nM) 
using a Modulus Microplate Mulitmode Reader (Turner Biosystems, California, USA).   
 
DCFH-DA fluorimetry ROS assay 
Oxidation of DCF-DA (2′,7′-Dichlorofluorescein diacetate) to dichlorofluorescein (DCF) was 
used to measure formation of reactive oxygen species by cell cultures.  Following treatment 
the medium above the cells was removed, wells were washed twice with phosphate buffered 
saline and 100µl of fresh FBS-free medium containing 10µM DCFH-DA was added to each 
well.  After 40 mins incubation oxidation of DCFH-DA to DCF was determined by 
fluorescence (excitation 485 nM; emission 535 nM) using a Modulus Microplate Mulitmode 
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Measurement of Ach, ATP and PGE2  
Samples for measurement of basal and stretch-induced release of these urothelial mediators 
were generated as previously described (McDermott et al. 2012).  Following 24 hr treatment 
with the parent drugs or metabolites, incubation medium was aspirated and cells were washed 
twice with Krebs bicarbonate solution (118.4 mmol/L NaCl, 24.9 mmol NaHCO3, 4.7 mmol 
KCl, 1.9 mmol CaCl2, 1.15 mmol MgSO4, 1.15 mmol KH2PO4 and 11.7 mmol glucose) prior 
to adding 150μl of Krebs bicarbonate solution to each well.  After 15 mins, the solution in each 
well was removed for measurement of basal ACh, ATP and PGE2 release from treated and 
control RT4 or T24 cells. Next, 150μl of hypotonic Krebs bicarbonate solution (50% of normal 
NaCl content) was applied to each well for 15 minutes. The use of hypotonic Krebs solution 
causes the cells to swell, mimicking the stretch that occurs during bladder filling.  The solution 
in each well was collected for analysis of stimulated mediator release.   
 
ACh release by urothelial cells was measured with an Amplex Red ACh/ACh esterase Assay 
Kit (Molecular Probes) and fluorescence measured using a Modulus Microplate Mulitmode 
Reader (Ex. 540 / Em. 590nm).  ATP release was measured using a luciferase-luciferin ATP 
Determination Kit (Molecular Probes).  The level of PGE2 released from cells was measured 
using Prostaglandin E2 EIA Kit (Cayman Chemicals).  The assays were performed according 
to manufacturer’s protocols. Mediator concentrations in samples were calculated using 
standard curves constructed from known ACh, ATP or PGE2 standards.  Concentrations of 
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Caspase-3 activity assay 
Caspase-3 activity was used as an index of apoptosis. RT4 and T24 cells were treated with 
acrolein (100µM), CAA (10µM), combination of acrolein and CAA,  or vehicle for 24h. 
Caspase-3 activity was then determined using a caspase-3 fluorescence assay kit (Cat #: 
10009135, Cayman Chemicals, Ann Arbor, USA). Caspase-3 activity was normalized for cell 
density (resazurin data) and expressed as a fraction of untreated vehicle control.  
 
LDH Activity Assay 
The presence of LDH in samples from cultured urothelial cells was measured using a LDH 
Cytotoxicity Assay Kit as measure of membrane integrity.  Cells were seeded and treated as 
described above and basal and hypotonic stretch samples were collected from each well and 
used for the LDH assay according to the manufacturers protocol.  
 
Statistical analysis 
Results were expressed as mean ± standard error of the mean (SEM).  Data were analysed using 
a Student t-test or one-way ANOVA with Dunnett or Tukey multiple comparisons test as 
appropriate, using Graphpad InStat3 software (SanDiego, CA). Significance levels were 
defined as p<0.05 (*), p<0.01 (**) and p<0.001 (***).  
 
Materials  
Chemicals were of analytic grade and obtained from Sigma-Aldrich (St Louis, USA).  
Cyclophosphamide (monohydrate salt), ifosfamide, acrolein, chloroacetaldehyde, resazurin 
salt, 2′,7′-dichlorofluorescein diacetate (DCF-DA) and salts for Krebs-bicarbonate solution 
were purchased from Sigma-Aldrich (St Louis, USA). 
9 
This is a post-peer-review, pre-copyedit version of an article published in Archives of Toxicology.  
The final authenticated version is available online at: http://dx.doi.org/10.1007/s00204-019-02589-1. 
 
Results 
Effects of cyclophosphamide, ifosfamide, acrolein and CAA on cell viability and ROS 
formation  
The toxicity of cyclophosphamide, ifosfamide, and the metabolites acrolein and CAA was first 
assessed in terms of ability to induce changes in urothelial cell viability and ROS formation.  
Twenty-four-hour exposure of either cell line to the parent compounds cyclophosphamide or 
ifosfamide at concentrations up to 100µM did not affect cell viability nor did either parent drug 
affect ROS formation (data not shown).  However, both urinary metabolites, CAA and acrolein 
caused concentration dependent decreases in urothelial cell viability and increase in ROS 
production (Fig. 1).   
On RT4 cells CAA was significantly more cytotoxic than acrolein and the mean IC50 value 
[10(8-14) µM] was significantly lower (p<0.01) than that for acrolein [67(47-95) µM] (Fig 1-
A).  Similarly, on T24 cells, CAA was significantly (p<0.05) more toxic than acrolein with an 
IC50 of CAA 4(3-5) µM compared with 15(12-14) µM for acrolein (Fig 1-B).  The cytotoxicity 
of CAA and acrolein was associated with increased ROS formation.  At 10µM in RT4 cells 
ROS formation induced by CAA was significantly greater (p<0.001) than that induced by 
acrolein (Fig 1-C).  In T24 cells, 1µM and 10µM CAA caused significantly greater (p<0.01) 
increases in ROS formation than acrolein at the same concentrations (Fig 1-D).  
 
These metabolites are present in the urine together, so a combination of the two was also 
investigated.  To determine whether the urinary concentration of acrolein (100nM) had an 
additive effect on the toxicity of CAA, a toxic CAA concentration was selected (10μM).  The 
combination of the urinary acrolein concentrations of 100nM and 10μM CAA caused a 
significant reduction in cell viability in T24 cells similar to the effect seen after CAA alone 
(Fig 1C).  However, in the RT4 cells, cell viability in the combination treated cells was 
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significantly higher than after CAA (10μM) alone.  ROS formation was also measured after 
treatment with the combination of acrolein (100nM) and CAA (10μM).  Again, in T24 cells 
the increase in ROS production after treatment with the combination of metabolites was similar 
to that observed with CAA (10μM) alone, whereas in RT4 cells ROS formation was 
significantly lower in the combination treated cells than after CAA (10μM) alone (Fig 1F).  
 
Protective effects of N-acetyl cysteine (NAC) 
To determine if ROS formation played a causal role in CAA or acrolein induced cytotoxicity, 
cells were treated with the metabolites in the presence or absence of NAC.  Acrolein (100μM) 
treatment caused basal ROS levels to increase to 305±8.9% of control levels in RT4 cells and 
to 1313±26.7% in T24 cells. NAC (300μM) prevented the increase in ROS production induced 
by acrolein in both cell lines, reducing ROS levels down to control levels in both cell lines 
(p<0.01) (Figure 2 A & B). Similarly, CAA increased ROS production to 242±16.6% and 
272±4.7% of control in RT4 and T24 cells respectively. Again, ROS production was restored 
to that of an untreated control by NAC (300μM) (103±5.8% of control in RT4 and 101±2.0% 
in T24 cells) (p<0.01) (Figure 2 C & D). Similar protective effects were seen with 1mM NAC 
(Figure 2), and so all further experiments using NAC were performed at the lower 
concentration (300µM) only. 
Acrolein (100μM) reduced cell survival to 37.2±2.4% in RT4 cells and 6.1±1.1% in T24 cells. 
The reduction in cell survival due to acrolein (100μM) was attenuated in the presence of NAC 
in both RT4 and T24 cells restoring cell viability to 83.7±5.2% and 84.9±6.6% of control 
respectively (p<0.01) (Figure 3A & B). Similarly, CAA (10μM) reduced cell survival in RT4 
cells to 62.0±2.8% of control and in T24 cells to 34.7±2%. Again, cell survival was restored to 
that of an untreated control by NAC (p<0.01) (Figure 3 C & D).  
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Twenty-four-hour exposure to acrolein, CAA or their combination was associated with a 
significant increase in caspase-3 activity in both cell line (Fig. 3E & F), with the exception of 
100µM acrolein in RT4 cells, where the increase was not statistically significant.  
Co-treatment with NAC (300μM) again protected urothelial cells from CAA (10μM), reducing 
caspase-3 levels from 269±37% down to 83.4±8.8% of control in RT4 cells and from 355±48% 
to 179±37% of control in T24 cells (p<0.05) (Figure 3E). The acrolein (100μM) induced 
increase in caspase-3 activity in T24 cells was also prevented by NAC with levels decreasing 
from 248±34% to 130±18% of control (p<0.05). NAC also protected urothelial cells from 
increased caspase-3 activity due to the combination of acrolein (100µM) with CAA (10μM) 
reducing levels in both cell lines (p<0.05) (Figure 3F). 
 
Effects of cyclophosphamide, ifosfamide, acrolein and CAA on cell mediator release 
Twenty-four-hour exposure of either cell line to 0.01-100µM cyclophosphamide or ifosfamide 
did not affect mediator release (data not shown).  Also, at concentrations up to and including 
10µM, acrolein had no effect on ATP, ACh or PGE2 levels in RT4 or T24 cells (Fig. 4 Data 
shown for 100nM acrolein).  However, CAA (10µM) in T24 cells, caused a significant increase 
in basal and stimulated ATP levels (3.5-fold increase in basal samples and 5-fold increase in 
stimulated samples, p<0.001) (Fig 4D).  Basal levels of ACh were significantly reduced while 
stimulated levels were significantly increased after treatment with 10µM CAA (50% decrease 
in basal levels p<0.05 and 2.5-fold increase in stimulated levels p<0.01) (Fig 4E).  In both cell 
lines, basal PGE2 levels were increased significantly (approximately 2.5-fold increase in both 
cell lines, p<0.05) after CAA treatment (10µM) (Fig 4C&F).  Treatment of RT4 or T24 
urothelial cells with acrolein and CAA in binary combination resulted in the same level of ATP, 
ACh and PGE2 release as treatment with CAA alone (Fig 4).  
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Acrolein had no effect on mediator release except at the highest concentration examined which 
is 1000-fold greater than that appearing in the urine of patients.  At this very high concentration 
(100µM), acrolein caused a 5-fold increase in basal ATP levels (p<0.001), 2.5-fold increase in 
stimulated ATP levels (p<0.05) (Fig 5A) and a 60% increase in stimulated acetylcholine levels 
(p<0.001) in RT4 cells (Fig 5 B).  PGE2 levels in basal and stimulated samples from RT4 cells 
were also increased after treatment with this high concentration of acrolein (7.5- and 4-fold 
respectively, p<0.001) (Fig 5C). No changes were observed in samples from T24 cells treated 
with 100µM acrolein as cell survival was too low.  
Analysis of extracellular LDH activity revealed no change following exposure to acrolein or 
CAA and following the mediator sample collection procedure, confirming that levels of ATP, 
ACh and PGE2 measured in samples were released from cells and were not simply leaking 
from damaged cells. 
Effects of N-acetyl cysteine on urothelial mediator release changes following acrolein or CAA 
treatment 
Acrolien and CAA induced cell death and ROS production in human urothelial cells (Figure 
1), with NAC offering protection against these changes (Figure 3) and so its protective effects 
on the functional changes to mediator release was considered next.  Acrolein (100μM) 
treatment in RT4 cells caused a significant increase in both basal and stimulated ATP, PGE2 
and ACh levels. These changes in mediator release could be prevented by co-treatment with 
NAC (Figure 5A-C) returning release of these mediators to levels comparable to untreated 
controls.  In T24 cells CAA (10μM) treatment caused a significant increase in both basal and 
stimulated ATP and PGE2 levels. Basal levels of ACh were reduced while stimulated levels 
were increased after CAA treatment. Co-treatment with NAC again prevented these changes 
in mediator release (Figure 5D-F).  
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Discussion and Conclusions 
Cyclophosphamide and ifosfamide treatment are associated with bladder toxicity.  The 
urothelium has been shown to be able to communicate with the detrusor, myofibroblasts and 
sensory nerves by releasing ATP, ACh and PGE2 among other mediators (Sellers et al. 2018).  
Changes in these transmitters have been linked to bladder function diseases and sensory 
changes.  This study is the first to focus on the effects of CAA on urothelial viability and 
functional mediator release, and compared to the effects of acrolein, the metabolite typically 
linked to bladder toxicity of cyclophosphamide and ifosfamide.   
 
In this study, urothelial cell viability was reduced by acrolein and by CAA confirming that both 
metabolites are toxic to the urothelium.  However, chloroacetaldehyde was more toxic to 
urothelial cells than acrolein, with a 7- and 4-fold greater cytotoxic potency in RT4 and T24 
cells respectively, based in IC50 values.  The reduction in cell viability after treatment with 
acrolein was accompanied by an increase in ROS production which is in line with previous 
studies.  CAA treatment at 10µM in both cell lines produced significant changes in both cell 
viability and ROS production but at 1µM ROS production did not change despite cell viability 
being significantly reduced.  This suggests that CAA toxicity at higher concentrations may 
involve ROS, similar to acrolein toxicity, while at lower concentrations it may induce an 
alternative cell death pathway.  A study by MacAllister et al. (2012) showed that depletion of 
the endogenous antioxidant GSH increased the toxicity of acrolein but not CAA in rat 
hepatocytes suggesting that CAA may cause cell death via a pathway other than ROS 
production.  This study has shown that CAA significantly affected urothelial cell viability and 
ROS formation at lower concentrations than that of acrolein suggesting that chloroacetaldehyde 
may also contribute to the urotoxicity of cyclophosphamide and ifosfamide, not just acrolein 
as previously thought. Nephrotoxicity is observed in patients following ifosfamide but not 
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cyclophosphamide treatment, and it is believed that CAA is responsible for renal toxicity as it 
is the main product of ifosfamide metabolism. Recent studies assessing the nephrotoxicity of 
CAA suggest that concentrations of 25-75 µM are clinically relevant (Benesic et al. 2014).  
Here we observed urothelial toxicity and altered urothelial function following exposure to 
concentrations of CAA below this range, with IC50 values of 10 (8-14) µM and 4 (3-5) µM, in 
RT4 and T24 cells respectively highlighting the relevance to clinically levels.   
 
Acrolein and CAA would be present in the urine together and this is the first study to consider 
the combined effect of the two toxic metabolites.  Surprisingly, combining the likely urinary 
concentration of acrolein (100nM) with a toxic concentration of CAA (10µM) was not more 
toxic than CAA treatment alone.  Rather, acrolein (100nM) appeared to have a slight protective 
effect against cell death and ROS formation when combined with CAA (10µM).   At lower 
concentrations, acrolein can affect transcription factors such as nuclear factor-kappa B (NF-
κB) (Horton et al. 1999) and activator protein-1 (AP-1) (Biswal et al. 2002; Korkmaz et al. 
2007). Both of these transcription factors can have anti- or pro-apoptotic effects. It is possible 
that 100nM acrolein, by way of transcription factors, may be having protective, anti-apoptotic 
effects and protecting the cells from CAA induced death.  This is consistent with our reported 
findings in the T24 cell line, where caspase-3 activity was equivalent in the acrolein and 
combination groups. 
 
The function of the urothelial cells that remain after treatment with cyclophosphamide and 
ifosfamide was also of interest in this study.  It is now well established that ATP plays a major 
role in bladder sensory mechanotransduction mechanisms.  There is basal release of ATP from 
urothelial cells (Kang et al. 2013a) and additional ATP release can be stimulated in response 
to stretch during bladder filling (Kang et al. 2013a; Sadananda et al. 2009).  Urothelial ATP 
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acts on P2X3 and possibly P2X2 receptors on sensory nerves to transmit the sensation of 
bladder filling to the CNS (Burnstock 2009).  ATP can have effects on both low and high 
threshold nerve fibres, altering the micturition reflex and pain sensations respectively 
(Burnstock 2009; Rong et al. 2002).  In our study acrolein and CAA increased both basal and 
stimulated ATP release from urothelial cells.  However, CAA was more toxic than acrolein, 
inducing the changes in ATP at a 10-fold lower concentration (10μM).  It is possible that higher 
basal ATP levels in patients treated with cyclophosphamide or ifosfamide may be responsible 
for the urinary frequency and feelings of residual volume experienced by patients.   An increase 
in stretch induced ATP levels after cyclophosphamide or ifosfamide treatment may also 
contribute to more frequent urges to urinate and could be responsible for the reported painful 
sensations as the bladder fills or on voiding.   
 
It has also been reported that ATP increases the excitability of afferent nerves (Burnstock 2011) 
and enhances its own release from urothelial cells (Birder 2010), while cyclophosphamide 
treatment enhances and sensitises P2X receptor activity (Dang et al. 2008).  Studies of a 
comparable disease in cats (i.e. feline interstitial cystitis) has demonstrated increased stretch-
evoked release of ATP from the urothelium as well as changes in purinergic receptor profiles 
in urothelial cells (Birder et al. 2003).  Therefore, the combined effect of more ATP and more 
sensitive purinergic receptors on afferent nerves is a likely explanation of the sensory changes 
seen after cyclophosphamide and ifosfamide treatment.  Both acrolein and CAA treatment 
resulted in an increase in ATP release from human urothelial cells and accordingly is likely to 
contribute to the urotoxicity of cyclophosphamide and ifosfamide.  However, CAA caused an 
increase in ATP at a lower concentration than acrolein potentially making CAA the more 
urotoxic metabolite.   
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The urothelium has also been shown to release ACh in response to stretch and is thought to act 
on muscarinic receptors on the urothelium and on the sensory nerves (Yoshida et al. 2006). 
The activation of urothelial muscarinic receptors leads to release of several substances 
including ATP and PGE2 as well as the urothelium derived inhibitory factor (UDIF) (Hanna-
Mitchell and Birder 2008; Hawthorn et al. 2000; Yokoyama et al. 2011). The effect of ACh on 
afferent nerves in the bladder is still unclear with both inhibitory and stimulatory effects 
reported (Daly et al. 2010; Iijima et al. 2007).  
 
Acrolein and CAA treatment both caused increased stretch-induced levels of ACh, however 
CAA was again the more potent metabolite inducing this change at a concentration (10μM) 10-
fold lower than acrolein (100μM).  The increased ACh during stretch may be acting directly 
on the detrusor muscle or the afferent nerves to affect functional and sensory changes in the 
bladder.  However, it is also possible that the change in ACh levels alters the release of other 
transmitters from the urothelium, indirectly contributing to the bladder changes after 
cyclophosphamide or ifosfamide treatment.  Specifically, more ACh may act in an autocrine 
manner causing greater ATP release which in turn could lead to sensory changes in patients.  
 
The urothelium expresses cyclooxygenase (COX)-1 and COX-2 enzymes which are 
responsible for the synthesis of prostanoids including prostaglandin E2 (de Jongh et al. 2009).  
Several studies in rats and mice have found that systemic treatment with cyclophosphamide, 
ifosfamide or intravesicular treatment with acrolein induces COX-2 expression in urothelium 
within 12-24 hours of treatment (Klinger et al. 2007; Macedo et al. 2008; Macedo et al. 2011) 
and one study found that the plasma PGE2 concentration was increased after administration of 
ifosfamide (Macedo et al. 2011).  However, the present study is the first to investigate the effect 
of acrolein and CAA on the release of PGE2 from urothelial cells. Acrolein treatment (100µM) 
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caused an increase in basal and stimulated PGE2 release from the urothelial cells.  CAA 
treatment (10µM) also caused significantly more basal PGE2 to be released from urothelial 
cells and while stimulated release was increased it was not significant.  PGE2 released from the 
urothelium is thought to activate or sensitize afferent nerves (de Groat and Yoshimura 2001) 
and cause stimulation of the detrusor muscle increasing resting tone and spontaneous 
contractions (de Jongh et al. 2007).  In addition, PGE2, released from afferent nerves or the 
urothelial cells and acting via EP1 and/or EP3 receptors on urothelial cells stimulates the 
release of ATP (Tanaka et al. 2011). Both metabolites caused higher basal PGE2 levels which 
may lead to sensitisation of afferent nerves and as a result altered micturition reflex, 
hyperactivity and feelings of residual volume. Furthermore, increased stimulated PGE2 release 
may contribute to the feelings of pain during filling or voiding experienced by patients treated 
with cyclophosphamide or ifosfamide.  Again, CAA appeared to be more potent inducing 
changes in PGE2 at a concentration (10µM) 10-fold lower than acrolein (100nM).   
 
Inthis study, NAC protected the urothelial cells from acrolein and CAA induced cell death and 
ROS formation restoring cell survival and ROS levels to that of an untreated control. 
Furthermore, NAC prevented the functional changes to acrolein or CAA in the cells, with levels 
of all mediators being the same as untreated controls. These are promising results as it appears 
NAC can fully protect urothelial cells from acrolein or CAA damage.  Few studies have looked 
at the ability of NAC to protect urothelial cells from cyclophosphamide or ifosfamide induced 
toxicity. In exfoliated bladder cells from mice treated with cyclophosphamide, with and 
without oral NAC supplementation, it was shown that genotoxicity, inflammatory infiltration 
and haemorrhage were prevented by NAC (Gurbuz et al. 2009).  However, NAC has shown 
similar protective effects against hepatotoxicity and nephrotoxicity (Chen et al. 2007; Chen et 
al. 2008; Hanly et al. 2012; Macallister et al. 2012; Mohammad et al. 2012). 
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Tanel and Averill-Bates (2007) demonstrated that the mechanism by which NAC protected 
chinese hamster ovary cells from acrolein cytotoxicity was by increasing intracellular GSH and 
preventing apoptosis. Furthermore, NAC has been shown to stop ROS induced apoptosis in 
human bladder urothelial cells due to sulforaphane and compound K (Jo et al. 2014). As 
described in the results above, NAC was able to prevent the increase in caspase-3 activity due 
to acrolein and CAA treatment of human urothelial cells supporting an anti-apototic 
mechanism of action. However, NAC also reduced ROS production in both cells lines which 
suggests that the mechanism of NAC protection may be the prevention of oxidative stress. 
From these results, NAC appears to be a promising alternative or addition to current 
uroprotective co-treatments for cyclophosphamide and ifosfamide therapy. NAC not only 
appears to protect urothelial cells from damage but also from the functional changes induced 
by acrolein and CAA. 
 
NAC given orally is excreted in the urine in the form of both NAC and cysteine (Ventura et al. 
2003) making it possible that a simple oral dose of NAC could protect patients from acrolein 
and CAA induced urotoxicity. For patients this could mean oral supplementation during and 
after treatment with cyclophosphamide or ifosfamide could reduce the pain, urinary frequency 
and urgency associated with these drugs and potentially improve treatment tolerability and 
outcomes. 
 
In summary, our study has demonstrated that both acrolein and CAA are toxic to the urothelium 
causing increased ROS production and decreasing cell viability.  Furthermore, both metabolites 
cause changes in urothelial mediator levels which could contribute to the sensory and 
functional changes experienced by patients after treatment with cyclophosphamide or 
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ifosfamide.  Specifically, increased ATP and PGE2 levels may cause sensitised afferent nerves 
leading to an altered micturition reflex, hyperactivity, feelings of residual volume and pain 
sensations.  CAA was shown to be more toxic to cultured human urothelial cells than acrolein, 
inducing significant changes at clinically relevant concentrations.  This study has shown that 
NAC appears to protect urothelial cells from the acrolein and CAA induced changes and 
accordingly may be useful in preventing urotoxicity in patients receiving cyclophosphamide 
and ifosfamide chemotherapy. 
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Fig. 1 Effect of 24 hour acrolein, chloroacetaldehyde (CAA) or combination treatment on cell 
viability and ROS production in RT4 (A, C, D & F) and T24 (B, C, E & F) human urothelial 
cells.  Data are shown as a percentage of control (mean ± SEM, n=6) and analysed by unpaired 
two-tailed t-test for A-D (**p<0.01, ***p<0.001vs CAA) or analysed by 1-way ANOVA with 
Tukey posttest for E & F (### p<0.001 vs control, ***p<0.001 vs acrolein (100nM), ^p<0.05 
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Fig. 2 Effect of NAC on ROS production in RT4 (A & C) and T24 (B & D) following acrolein 
or CAA treatment. Data presented as mean ± SEM (n=6) and analysed by 1-way ANOVA with 
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Fig. 3  Effect of NAC on changes in cell viability and caspase-3 activity caused by 24-hour 
exposure to acrolein or CAA.  Data are shown as a percentage of untreated control (mean ± 
SEM, n=6) and analysed using 1-way ANOVA with Dunnett’s posttest (A-D *vs Control 
Acrolein or CAA in absence of NAC) or Tukey-Kramer posttest (E-F * with vs without NAC, 
^ vs untreated control) 
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Fig. 4 Effect of 24 hour acrolein (100nM), chloroacetaldehyde (CAA) (10µM) or acrolein 
(100nM) combined with CAA (10µM) treatment on basal and hypo-osmotically stimulated 
ATP, ACh and PGE2 levels in RT4 (A, B & C respectively) and T24 cells (D, E & F 
respectively). Data are shown as mean ± SEM (n≥6) and analysed using 1-way ANOVA with 
Dunnett post-test or Students t-test. (# p<0.05, ## p<0.01, ### p<0.001 vs control & * p<0.05, 
** p<0.01, *** p<0.001,vs acrolein) 
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Fig. 5 Effect of 24 hour treatment with acrolein in RT4 (A-C) or CAA in T24 (D-F) cells on 
basal and hypo-osmotically stimulated ATP and acetylcholine and PGE2 levels in the absence 
and presence of NAC.  Data are shown as mean ± SEM (n=6) and analysed using 1-way 
ANOVA with Dunnett post-test or Students t-test. (*vs control, # vs acrolein or CAA in the 
absence of NAC) 
